509 results
Page 4 of 26
CORRESP
76f0i3ubim64 gzk
6 Jan 21
Correspondence with SEC
12:00am
UPLOAD
srvr4t jr
23 Dec 20
Letter from SEC
12:00am
8-K
EX-99.1
t23yk24 bjk85
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K/A
EX-99.1
3x7s9kjg1w 9j
10 Dec 20
Financial Statements and Exhibits
4:13pm
8-K
80crm z7mf
3 Dec 20
Other Events
12:00am
8-K
038uu4suv2ar7onifzr
23 Nov 20
Other Events
8:32am
8-K
vgszkk
30 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:07pm
8-K
EX-99.1
7lo0qlqzkznpwmjal
30 Oct 20
Ligand Reports Third Quarter 2020 Financial Results
8:03am
8-K
EX-99.1
4ypngk4ioe1 y4hb1n
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
u7bisnem 0wpk457m
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-2.1
o46 l0j73lldt8
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
u5yjzzpbj01keulth2
1 Oct 20
Contingent Value Rights Agreement
8:42am
8-K
EX-99.3
zh0ajx9
1 Oct 20
Contingent Value Rights Agreement
8:42am
SC TO-T/A
EX-99
lhe3us e0
30 Sep 20
Third party tender offer statement (amended)
8:06am
SC TO-T/A
ckfn49h6kb
16 Sep 20
Third party tender offer statement (amended)
6:05am
SC TO-T/A
oy7ml9aj2 mps6kt
11 Sep 20
Third party tender offer statement (amended)
6:07am